Vivo Ventures, a Palo Alto, California, Shanghai, and Chengdu, China-based healthcare investment firm, has held the final close of its Fund VII, at $375m.
Backers in Vivo Ventures VII include pension funds, funds of funds, university endowments, foundations, financial institutions, and family offices adding a number of new investors from the U.S., Europe, and Asia.
Vivo VII will focus on investing the capital primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China. The firm plans to continue assisting companies in both countries in their efforts to forge cross-border partnerships, enabling them to acquire new products and expand the market for their existing products. It will also intends to identify later stage products with a high probability of FDA approval, and invest directly in public companies.
Managing partners of Vivo VII are Drs. Frank Kung, Albert Cha, Edgar Engleman, Chen Yu, and James Zhao.